CD274 and neoplasm: Immune checkpoint inhibitors block these effectors, exerting an anti-tumor effect (described elsewhere) [98]. Combined application of cuproptosis-activating agents and anti-PD-L1 or immune checkpoint inhibitors represent a potential area for future investigations.